Janssen Pharmaceutical Inc., a subsidiary company of Johnson & Johnson announced the FDA approval of drug Darzalex Faspro for the treatment of Multiple Myeloma Cancer.
IDEAYA Biosciences, Inc. and GlaxoSmithKline plc. announced a strategic partnership to develop solutions in the field of Oncology.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3868
Published Date: Aug 04, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing need for targeted drug delivery to treat cancer is estimated to boost the market growth.
The market is anticipated to attain a CAGR of ~5.5% over the forecast period, i.e., 2023 – 2035.
The North American region is anticipated to provide more business opportunities over the forecast period owing to the advancement in technology in the healthcare sector.
The major players in the market are Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited, and others.
The injectable segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.